Skip to main content
Bottles with blue caps)

Product Pipeline

Focused on Innovation

CSL is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. Working every day as if people’s lives depend on it, CSL’s R&D fuels the company’s sustainable growth by advancing world-class science, technology and collaboration. Our strong R&D pipeline utilises its expertise in plasma fractionation, recombinant technology, cell and gene therapy and vaccines to develop and deliver innovative medicines that address unmet medical needs or enhance current treatments in six Therapeutic Areas - Immunology, Haematology, Respiratory, Cardiovascular and Metabolic, Transplant and Vaccines. Our R&D portfolio focuses on innovation in new products, improved products and manufacturing expertise ensuring our continued growth.

Core Capabilities

as demonstrated in our product pipeline 

Phase I

Phase II

Phase III

Registration / Post-Registration

R&D Portfolio
Phase III

Garadacimab Anti-FXIIa mAb (HAE)

Humanised anti-factor XIIa monoclonal antibody for the potential treatment of Hereditary Angioedema (HAE) by subcutaneous administration.

HIZENTRA® (DM)

20% subcutaneous immunoglobulin for the treatment and long-term maintenance therapy of adults with Dermatomyositis (DM).

EtranaDez Etranacogene dezaparvovec (Haem B)

Recombinant adeno-associated viral vector of serotype 5 (AAV5) gene therapy containing the Padua variant of a codon-optimized human FIX complementary deoxyribonucleic acid (AAV5-Padua hFIX) for the treatment of Haemophilia B.

KCENTRA® 4F-PCC (Trauma)

A 4-factor prothrombin complex concentrate (4F-PCC) for the potential treatment of massive hemorrhage associated with severe traumatic injury.

CSL112 ApoA-I (AMI)

Novel apolipoprotein A-I infusion therapy to potentially reduce the risk of major adverse cardiovascular events (MACE) in patients with myocardial infarction (AMI).

Clazakizumab Anti-IL-6 mAb (AMR)

Humanized recombinant monoclonal antibody targeting interleukin-6 (IL-6) for the potential treatment of chronic active antibody-mediated rejection (AMR), the leading cause of long-term rejection in kidney transplant recipients.

CSL964 Alpha-1 Antitrypsin (Prevention of GvHD)

Prevention of acute Graft-versus-Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).

CSL964 Alpha-1 Antitrypsin (Treatment of GvHD)*

Treatment of steroid refractory, acute Graft-versus-Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).
*In collaboration with Blood and Marrow Transplant Clinical Trials Network (BMT CTN)

Registration / Post-Registration

HAEGARDA® (HAE)

Self-administered, subcutaneous C1-esterase inhibitor (human) for routine prophylaxis to prevent HAE attacks.

HIZENTRA® (SCIg) 20% Liquid

20% subcutaneous immunoglobulin.

PRIVIGEN® (IVIg) 10% Liquid

10% intravenous immunoglobulin.

AFSTYLA® rFVIII (Haem A)

Novel, recombinant factor VIII product for the treatment of adults and children with haemophilia A.

IDELVION® rFIX-FP (Haem B)

Novel, long-acting recombinant factor IX product for the treatment of haemophilia B.

ZEMAIRA®/RESPREEZA® Alpha-1 Proteinase Inhibitor (AAT Deficiency)

Alpha-1 Proteinase Inhibitor (Human) for treatment of Alpha-1 Antitrypsin (AAT) Deficiency.

FOCLIVIA®/FOCETRIA Adjuvanted Egg-based Influenza A (H5N1) Vaccine

Pre-pandemic, egg-based vaccine combined with Seqirus' proprietary adjuvant, MF59® (an additive that acts to strengthen the immune response to vaccination), to protect against influenza A (H5N1) - the 'bird-flu' strain.

AUDENZTM Adjuvanted Monovalent Influenza A (H5N1) Vaccine

Pre-pandemic, cell-based vaccine combined with Seqirus' proprietary adjuvant, MF59® (an additive that acts to strengthen the immune response to vaccination), to protect against influenza A (H5N1) - the 'bird-flu' strain.

AFLURIA® QUAD Egg-based Influenza Vaccine

Seasonal egg-based, split virion quadrivalent influenza vaccine registered in the US and Australia for use in children 6 months of age and older.

FLUAD® Trivalent Adjuvanted Influenza Vaccine

Seasonal, egg-based trivalent vaccine combined with Seqirus' proprietary adjuvant, MF59® (an additive that acts to strengthen the immune response to vaccination) to protect against three different strains of influenza.

FLUAD® Quadrivalent Adjuvanted Influenza Vaccine

Seasonal, egg-based quadrivalent vaccine, combined with Seqirus' proprietary adjuvant, MF59® (an additive that acts to strengthen the immune response to vaccination) to protect against four different strains of influenza.

FLUCELVAX® Quadrivalent Cell-based Influenza Vaccine

Seasonal cell culture-based, quadrivalent influenza vaccine offering protection against four different strains for use in children 6 months of age and older.

PANVAX® Egg-based Influenza Vaccine

Pre-pandemic, egg-based vaccine to protect against influenza A (H1N1) - the 'swine-flu' strain.